Cargando…
[Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients
OBJECTIVE: To describe the marginal cost and survival of patients treated with tocilizumab in a university hospital under real-life conditions and to evaluate factors that could influence costs and health outcomes will be evaluated. METHODS: Observational, single-center, retrospective study of a coh...
Autores principales: | Garcia-Molina, A., Alos-Almiñana, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794483/ https://www.ncbi.nlm.nih.gov/pubmed/36707309 http://dx.doi.org/10.1016/j.farma.2022.12.014 |
Ejemplares similares
-
Resultados en la práctica asistencial y coste marginal del tratamiento con tocilizumab en pacientes COVID-19
por: Garcia-Molina, Antonio, et al.
Publicado: (2023) -
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022) -
Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020) -
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
por: Stone, John H., et al.
Publicado: (2020) -
Efficacy and safety of tocilizumab in COVID-19 patients
por: Zheng, Kai-Lian, et al.
Publicado: (2020)